Clinical Trials Logo

Neoplasms, Second Primary clinical trials

View clinical trials related to Neoplasms, Second Primary.

Filter by:

NCT ID: NCT03101579 Completed - Clinical trials for Leptomeningeal Metastases

Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer

Start date: March 1, 2017
Phase: Phase 1
Study type: Interventional

It has been proved that intrathecal chemotherapy is the main treatment strategy for leptomeningeal metastases. At present, the commonly used drugs for intrathecal chemotherapy include methotrexate, cytarabine, and liposomal cytarabine. In recent decades, no new effective drugs have been discovered for intrathecal chemotherapy. The recurrence of leptomeningeal metastases is inevitable even after aggressive treatment. There is no effective treatment for recurrent leptomeningeal metastases after comprehensive treatment which includes intrathecal methotrexate and/or cytarabine, central nervous system radiation therapy, systemic chemotherapy as well as tyrosine-kinase inhibitor drugs. The quality of life is extremely poor, and the patients always die in short time. Pemetrexed is a newer multitargeted antifolate which has shown activity in various tumors. It has higher effectiveness and safety, which has been used as the first-line treatment of non-small cell lung cancer. In animal studies, pemetrexed was demonstrated to suppress tumor growth completely in mice with two types of transplanted human colon xenografts resistant to methotrexate. Therefore, the purpose of the study is to evaluate the safety and feasibility of intrathecal pemetrexed in patients with recurrent leptomeningeal metastases from non-small cell lung cancer.

NCT ID: NCT03101358 Completed - Clinical trials for Cutaneous Metastasis

Study of Topical SOR007 Ointment for Cutaneous Metastases

Start date: January 31, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum tolerated dose.

NCT ID: NCT03088150 Recruiting - ColoRectal Cancer Clinical Trials

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation

COLLISION
Start date: July 13, 2017
Phase: N/A
Study type: Interventional

The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.

NCT ID: NCT03075072 Recruiting - Brain Metastases Clinical Trials

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Start date: April 10, 2017
Phase: N/A
Study type: Interventional

This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)

NCT ID: NCT03031444 Completed - Metastasis Clinical Trials

Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis

PARECEC
Start date: January 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study was designed to analyze the prognosis and recurrence predictive factors of high risk patients (Clinical Risk Score≥3) of resectable colorectal liver metastasis. The efficacy of perioperative chemotherapy plus cetuximab and chemotherapy alone was compared for these patients.

NCT ID: NCT03029988 Terminated - Liver Metastases Clinical Trials

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

Start date: July 26, 2017
Phase: Phase 1
Study type: Interventional

Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.

NCT ID: NCT03027544 Recruiting - Brain Metastases Clinical Trials

Tomotherapy for Refractory Brain Metastases

TRBM
Start date: September 1, 2014
Phase: N/A
Study type: Interventional

This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for refractory brain metastases.

NCT ID: NCT03027284 Completed - Solid Tumor Clinical Trials

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Start date: February 3, 2017
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

NCT ID: NCT03026998 Active, not recruiting - Clinical trials for Hereditary Retinoblastoma

MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)

DepiSCARRH
Start date: March 19, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the benefit of MR screening for asymptomatic head & neck (or CNS) second primary cancers occurring in hereditary retinoblastoma patients previously treated by external beam radiation therapy (EBRT).

NCT ID: NCT03009058 Terminated - Metastatic Cancer Clinical Trials

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

MODULATE
Start date: May 24, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type. The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.